These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 18558665)

  • 1. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
    Dank M; Zaluski J; Barone C; Valvere V; Yalcin S; Peschel C; Wenczl M; Goker E; Cisar L; Wang K; Bugat R
    Ann Oncol; 2008 Aug; 19(8):1450-1457. PubMed ID: 18558665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.
    Pozzo C; Barone C; Szanto J; Padi E; Peschel C; Bükki J; Gorbunova V; Valvere V; Zaluski J; Biakhov M; Zuber E; Jacques C; Bugat R
    Ann Oncol; 2004 Dec; 15(12):1773-81. PubMed ID: 15550582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
    Curran D; Pozzo C; Zaluski J; Dank M; Barone C; Valvere V; Yalcin S; Peschel C; Wenczl M; Goker E; Bugat R
    Qual Life Res; 2009 Sep; 18(7):853-61. PubMed ID: 19568958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
    Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
    J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
    Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.
    Koutras AK; Gerolymos MK; Kontogeorgou E; Iconomou G; Vourli G; Tsiata E; Makatsoris T; Chrysanthopoulos C; Kalofonos HP
    J Chemother; 2007 Dec; 19(6):724-30. PubMed ID: 18230557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing.
    Koucky K; Wein A; Konturek PC; Albrecht H; Reulbach U; Männlein G; Wolff K; Ostermeier N; Busse D; Golcher H; Schildberg C; Janka R; Hohenberger W; Hahn EG; Siebler J; Neurath MF; Boxberger F
    Med Sci Monit; 2011 May; 17(5):CR248-58. PubMed ID: 21525806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
    Pinto C; Di Fabio F; Siena S; Cascinu S; Rojas Llimpe FL; Ceccarelli C; Mutri V; Giannetta L; Giaquinta S; Funaioli C; Berardi R; Longobardi C; Piana E; Martoni AA
    Ann Oncol; 2007 Mar; 18(3):510-7. PubMed ID: 17164226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
    Assersohn L; Brown G; Cunningham D; Ward C; Oates J; Waters JS; Hill ME; Norman AR
    Ann Oncol; 2004 Jan; 15(1):64-9. PubMed ID: 14679122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
    J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
    Kim ST; Kang WK; Kang JH; Park KW; Lee J; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Park YS; Im YH; Park K
    Br J Cancer; 2005 May; 92(10):1850-4. PubMed ID: 15870718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
    Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
    Moehler M; Kanzler S; Geissler M; Raedle J; Ebert MP; Daum S; Flieger D; Seufferlein T; Galle PR; Hoehler T;
    Ann Oncol; 2010 Jan; 21(1):71-7. PubMed ID: 19605504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
    Dalla Chiesa M; Tomasello G; Buti S; Rovere RK; Brighenti M; Lazzarelli S; Donati G; Passalacqua R
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):41-8. PubMed ID: 20204366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
    Blanke CD; Haller DG; Benson AB; Rothenberg ML; Berlin J; Mori M; Hsieh YC; Miller LL
    Ann Oncol; 2001 Nov; 12(11):1575-80. PubMed ID: 11822757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
    Samalin E; Afchain P; Thézenas S; Abbas F; Romano O; Guimbaud R; Bécouarn Y; Desseigne F; Edeline J; Mitry E; Bouché O; Adenis A; Aparicio T; Dorval E; Kramar A; Ychou M
    Clin Res Hepatol Gastroenterol; 2011 Jan; 35(1):48-54. PubMed ID: 21634054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
    Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
    J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.
    Bouché O; Raoul JL; Bonnetain F; Giovannini M; Etienne PL; Lledo G; Arsène D; Paitel JF; Guérin-Meyer V; Mitry E; Buecher B; Kaminsky MC; Seitz JF; Rougier P; Bedenne L; Milan C;
    J Clin Oncol; 2004 Nov; 22(21):4319-28. PubMed ID: 15514373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E
    Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.